Ferring Investing $32M In New Saint-Prex, Switzerland Biotech Center

The pharmaceutical company will expand its capabilities in biologics through a new biotech center at its global headquarters and manufacturing site in St Prex, Switzerland.


https://businessfacilities.com/2018/02/ferring-investing-32m-new-saint-prex-switzerland-biotech-center/
The pharmaceutical company will expand its capabilities in biologics through a new biotech center at its global headquarters and manufacturing site in St Prex, Switzerland.
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Ferring Investing $32M In New Swiss Biotech Center

The pharmaceutical company will expand its capabilities in biologics through a new biotech center at its global headquarters and manufacturing site in Saint-Prex, Switzerland.

Ferring Investing $32M In New Saint-Prex, Switzerland Biotech Center

Ferring Pharmaceuticals is expanding its capabilities in biologics through a new biotech center to be built at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland. Over the next three years, Ferring will invest approximately $32 million in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.

St Prex, Switzerland
Ferring’s headquarters have been located in Saint-Prex since 2006. (Photo © Ferring)

“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas, and will open up additional opportunities for Ferring to help people live better lives.”

In addition to the discovery, development and manufacture of new biologics, the active pharmaceutical ingredient (API) for Rekovelle® (follitropin delta), Ferring’s latest fertility treatment, will also be manufactured at the new Ferring Biotech Centre.

Earlier this year, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics to create innovative solutions for patients.

Founded in 1950, Ferring employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Suggested Links:

You Might Like:

LEAVE A REPLY